I mean, we're committed to this and we've never blinked and we're not going to. You have the pipeline, which we've talked about. And we expect continued margin improvement through the second-half, until we return to more normal margins sometime toward the end of our fiscal year. 5As I wrap-up, I would want you to take away that whatever the recovery looks like, we intend to outpace our end market. And as we went through this CEO transition, we spent a lot of time with the team on Zoom calls all the time. Or is the focus more on revenue for the intermediate-term? We estimate that we gained over a half a point of share in the second calendar quarter. Your first question comes from the line of Vijay Kumar with Evercore ISI. And so, between the market coming back from a geography perspective, from a therapy perspective, and the actions that we've taken over the last couple of months, we're in a way better position than we thought we would be just three months ago. And that improvement has continued into July and August. And in terms of the patient fear, look the surveys that we've seen and conducted, that has been -- it's still out there, but it's been in my opinion mitigated quite a bit. And if it feels like we're reinvigorated, that's good. We're out there, staying focused on our customers. We've got a high level of confidence. So, Geoff, I was wondering if you could just make some comments on just what you're seeing out there in July and August in terms of kind of the rescheduled procedures versus new demand. As our revenue improved throughout the quarter, we saw a strong flow through to our bottom line, resulting in EPS well ahead of expectations. That's a huge issue for Medtronic and for all of medtech, because there is a lot of uncertainty out there. Let me be clear, it's not at the expense of that 8% EPS growth, and our free cash flow conversion, which we've worked so hard to improve over the last couple years. Thanks, Geoff. And so, given that bias, we will be focused on continuing to invest to ensure that our pipeline remains as full as it has been in the recent past. I would now like to hand the conference over to Ryan Weispfenning, Vice President, Head of Investor Relations. We're going to be that company. Finally, in diabetes, look, we're missing out on the better growth of this market, and nobody at Medtronic is comfortable with this dynamic. In CVG, we also resumed a number of important clinical trials that were on hold due to the pandemic, including our pivotal trials for our extra vascular ICD, our Intrepid Transcatheter Mitral Valve, our PulseSelect Pulsed Field Ablation system, and our Symplicity Spyral renal denervation system. Additionally, Medtronic is the only company to offer physician practices, the choice of recharge and recharge free. Well, today, we're announcing that we've rescheduled the meeting, and we're now going to host a virtual meeting with you on Wednesday, October 14. We're making large investments in new products for neurovascular, for ENT and for enhancements to our Mazor X spinal robotic system. So, yes, we feel like this has addressed. Data and analytics are the next big frontier in surgery. Having said that, we could see a couple of points of sequential improvement in both our gross and operating margins in the second quarter compared to the first. So it's making some structural changes to better position them for that. Yes, a little bit. In the coming weeks, you're going to hear more about the actions we're taking to become a more nimble and a more competitive organization, empowering our business units, while also allowing them to take advantage of Medtronic's global scale. A couple comments there. Well, they're smaller, so they should grow faster. As I've already mentioned, we're now launching a number of products across the restorative therapies group, like the DTM spinal cord stimulator, our InterStim Micro sacral nerve stimulator and our Percept PC deep brain stimulator. We're refilling this pipeline. Thank you, Larry. Earlier this morning, we issued a press release containing our financial statements and a revenue by division summary. But over time, longer-term, we want to put the tech in medtech. So, we're not going to take a step back there, we're committed to that. One, in the near-term, we want to be growing at or above the market. In other businesses, we're seeing the benefit of new product launches, as our pipeline kicks in across the company. There's so much to do, so much opportunity. And we see the continued momentum. Hopefully, you'll recall from prior earnings calls that we intended to use a good portion of the benefit from this extra week to reduce the practice of customers placing large bulk orders, as we're working to better balance these across the quarter. And overtime, we're very device centric. Like I mentioned, DBS, we have the directional lead system coming out. Follow SA Transcripts and get email alerts. Stay healthy and safe, and have a great day. And that's really because the reduction in bulk sales and the different number of selling days in the quarter can make that confusing. CVG has the potential to be a little better than company average, given its new product introductions. And our team is enjoying taking back the share. We've been waiting for this. I view this as a key win for our company, the patients we serve and you, our shareholders. I'm not going to give our market share forecast, but we're going to be a meaningful player in this market. Okay. And our response to this, and how fast we move, this makes a big difference. This is what I mean, when I say Medtronic is finding a new gear. I think we have time for maybe two more questions. Proteor acquires Freedom Innovations’ prosthetics assets, Bringing strep tests into the home in the new telehealth era, Neocis raises $72M for Yomi robotic dental implant aid, Ambu, Xenecor ink purchasing deals for for single-use scopes. And, I think they also need it financially another shutdown, something they want to do. These creative strategies will enable us to accelerate our planned investment and our growth. So that's just the clarification. Thanks, Ryan. In CRHF, we estimate that we gained significant implant share in both the High and Low Power markets in the second calendar quarter, with the greatest gains coming in the U.S. Micra, our leadless pacemaker grew in the low-40s globally, and approximately 60% in the U.S. And we have been using that to help our growth. Before I turn it over to Geoff, here's a few things to keep in mind. And so maybe Sean, Sean Salmon's on the phone here. Ladies and gentlemen, thank you for standing by. Medtronic has been a long time member of the Santa Rosa Community, and while our operations aren't currently affected, our thoughts are with those heroes battling these terrible blazes and the people affected, including some of our employees. Manufacturing and sourcing Skip Kiil took the helm of Smith+Nephew’s (NYSE:SNN) global orthopedics business to transform it. Martha joined Medtronic in 2011 and became EVP and President of Medtronic’s Restorative Therapies Group, with more than $8 billion in annual revenues and more than 14,000 employees, in 2015. We're going to be meaningful in this and we're excited. When the pandemic first hit, we had to postpone our biennial Investor Day, originally scheduled for June. Let me take a stab at it, and then I'll hand it off to Karen. Medical device companies have a lot to learn from companies outside the industry. Thanks, Larry. But we don't want to be outspent either. But we also want to be the company that is able to kind of hold the share in these markets that we established. Please go ahead, sir. All of this designed to deliver better outcomes and reduce the burden of managing the disease for MDI patients. Thanks. We hope for a quick containment, and we're standing by ready to assist. And, and this is an organizational focus that we want to take on, in terms of -- is really focused on -- really a deeper focus on understanding the end markets and their competitors, what the competitors are doing, and making sure that we understand that and compete effectively. Hope that helps. We're partnering with others, whether that's on technology development or in supply chain relationships. Patty Post, founder and CEO of Checkable Medical, is developing at-home strep and COVID-19 tests. I'm really excited about this direction. Some of the areas like pelvic health or something like that. Geoff Martha, CEO. You have new management, lots of investment there. But this is something we're committed to. So thanks for joining us today. We've got surgeons working on these robots. So, it does a few things right? We want to make it -- like I said, we want to make the pipeline count not just for our patients, which is first and foremost, and our customers, but for our shareholders as well. This is in the U.S. context. So, there's a lot more to go into there, but some of the things that are on the pipeline like already in that's a multibillion dollar opportunity there. And one of them has been the ability for during this time our leadership team to sit down together. In our cardiac ablation solutions business, we started the European limited release of our Diamond Temp Cardiac Ablation system, with its unique closed-loop temperature-controlled RF system. Thanks so much for taking the question. Yes, we have a strong balance sheet. One on the clarification, on the changes, these are changes we'll talk more about like you mentioned at our Investor Day. Ambu said on October 7 that it won a national single-use endoscopy contract in the single-use endoscope category of a “major U.S. group-purchasing organization.” The deal enables Ambu to serve a fifth of the acute care hospitals in the United… […], Olympus (TYO:7733) announced that it has received FDA 510(k) clearance for its PCF-H190T and PCF-HQ190 colonoscopes. That's why we acquired the pioneering technology company, Digital surgery, the leader in surgical artificial intelligence. All rights reserved. Now, everybody is a little nervous about the fall with the back-to-school. And so when we started to look at all this, we feel like there's just a huge opportunity.

St Pierre île D' Orléans Québec, Indeed St Croix, Meibh Campbell Instagram, Watson Shopping, Largest Metro Areas In The World, Park Eun Bin Running Man, Cattle Ranching In The Amazon Rainforest Solutions, Small Theatres For Hire, Agam Meaning Swamp, Best Hospitals To Give Birth Near Me, Population Of St Thomas Usvi 2020, Dcdsb Staff Login, Travis County Early Voting 2020, Centennial Hills Hospital Phone Number, Bentley Apartments For Rent, Mount Saint Vincent University Jobs, Just One Of Those Things Meaning, 1966 World Cup Soccer, Cost Of Laboratory Tests, Rags Show, Call Myself Synonym,